Johnson & Johnson provides updated results from Phase 1b TRIMM-2 study

Johnson & Johnson announced updated results from the investigational Phase 1b TRIMM-2 study evaluating the combination of TALVEY with DARZALEX FASPRO and pomalidomide in patients with relapsed or refractory multiple myeloma that demonstrated an overall response rate of 82%, further supporting the investigation of this combination. The results from the Phase 1b TRIMM-2 study evaluating TALVEY, the first bispecific T-cell engager to target GPRC5D, combined with DARZALEX FASPRO, the first subcutaneous anti-CD38 monoclonal antibody, and pomalidomide included patients who received at least three prior lines of therapy, including a proteasome inhibitor and immunomodulatory drug, or were double refractory to a PI and IMiD and had not received anti-CD38 therapy in the previous 90 days. At data cutoff, 77 patients had received TALVEY in doses of 0.4 mg/kg weekly or 0.8 mg/kg biweekly, with step-up doses, combined with DARZALEX FASPRO and pomalidomide. In the QW arm, the overall response rate was 100 percent, with 56 percent having a complete response or better. The Q2W arm achieved 76 percent ORR, with 56 percent achieving CR or better. The median duration of response in the Q2W arm was 26.4 months, and the median progression-free survival was 20.3 months. Results showed 52 percent of patients who are anti-CD38 refractory achieved CR or better and 70.8 percent of patients who received prior chimeric antigen receptor T cell therapy achieved CR or better. Patients who had received prior bispecific antibodies achieved an 82.8 percent ORR.